Watmind Completed Millions of Dollars In Series B Financing, focusing On POCT Chemiluminescence

According to VCBeat, Watmind just completed millions of dollars in Series B Financing. This round of financing was led by Guozhong Venture Capital, the funds will be used to improve products in the fields of microfluidics and POCT chemiluminescence.

Watmind was founded back in 2014, it mainly focuses on the R&D in the fields of microfluidics and POCT chemiluminescence. Right now, the clinical products of Watmind have been introduced to more than 100 hospitals in China, and are used in departments such as cardiology, emergency department, heart failure center, chest pain center and more. Helping to improve the speed of diagnosis and monitoring patients’ condition.

Watmind integrates reagents and blood separation devices into the chip through the pioneering microfluidic technology to achieve fast detection. At the same time, Watmind uses a double-anti-sand chemiluminescence method with magnetic particle separation to achieve an active immune response. Right now, Watmind is preparing to expand overseas.

Shenzhen Guozhong Venture Capital Management is an investment firm in China. It manages around 6 Billion RMB of funds.